China Resources Sanjiu Medical & Pharmaceutical Co (000999) Fair Value & Analysis

Healthcare · CN · Market cap 40.9B CNY

A solid business, screening 80% undervalued on our models.

What matters now

• The price is below even our cautious bear case (¥33.93). The market is more pessimistic than our downside scenario.
• Solid quality (59/100) at a price below fair value, the discount is the argument here, not the business quality.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.

How to read this chart

60‑month range ¥12.00 – ¥37.18 · fair‑value band ¥33.93 – ¥56.54 · the ¥25.13 price screens below the ¥45.23 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 24, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

China Resources Sanjiu Medical & Pharmaceutical Co (000999) currently trades at ¥25.13, while our model-based Fair Value estimate is ¥45.23, implying the stock looks roughly 80.0% undervalued today. The Quality Score stands at 59/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, China Resources Sanjiu Medical & Pharmaceutical Co generated revenue of 32.9B CNY at a net margin of 9.8%. Revenue grew 18.6% year over year. It earns a return on equity of 10.8%. Net debt stands at 1.8B CNY. Fundamentals as of Jul 24, 2026

Our scenario range runs from ¥33.93 (bear case) to ¥56.54 (bull case); at ¥25.13, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 80%, 000999 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (¥58.84) versus Asset-Based (¥8.93). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in the People's Republic of China and internationally.

Full company description

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in the People's Republic of China and internationally. The company offers health consumer products (CHC), including cold, flu, skin, gastrointestinal, cough, orthopedics, pediatrics drugs, and dietary nutritional supplements; and prescription drug products, such as anti-tumor, cardiovascular and cerebrovascular, digestive system, orthopedics, pediatrics, anti-infection, and other treatment areas; Chinese medicine health products; and vitamins, minerals, protein powder, collagen, probiotics, health foods, and formula granules. It also provides related health services. The company was formerly known as Sanjiu Pharmaceutical Co., Ltd. and changed its name to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. in February 2010. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. was incorporated in 1999 and is headquartered in Shenzhen, China. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a subsidiary of China Resources Pharmaceutical Group Limited.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

China Resources Sanjiu Medical & Pharmaceutical Co reported revenue of ¥31.6B in FY2025 versus ¥15.5B in FY2021, a compound +19.4%/yr. Reported net income was ¥3.4B in FY2025, compounding +13.6%/yr from FY2021.

Watch 000999: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.